EP Patent

EP2968286B1 — 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities

Assigned to Deciphera Pharmaceuticals LLC · Expires 2017-09-13 · 9y expired

What this patent protects

Patent listed against Romvimza.

Drugs covered by this patent

Patent Metadata

Patent number
EP2968286B1
Jurisdiction
EP
Classification
—
Expires
2017-09-13
Drug substance claim
No
Drug product claim
No
Assignee
Deciphera Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.